Top Page
Avacta Group plc
(LSE:AVCT)
Avacta Group plc (AVCT) vs. iShares MSCI United Kingdom ETF (EWC)
Avacta Group plc Business Overview & Revenue Model
Avacta Group plc Earnings Call Summary
Avacta Group plc Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.62M | 113.00K | 2.85M | 9.65M | 2.94M | 2.14M |
| Gross Profit | 7.55M | 113.00K | 2.84M | 4.23M | -2.50M | -973.00K |
| EBITDA | -15.07M | -17.62M | -14.12M | -34.78M | -26.69M | -16.40M |
| Net Income | -25.89M | -52.84M | -24.95M | -36.94M | -26.32M | -18.89M |
Balance Sheet | ||||||
| Total Assets | 89.29M | 48.27M | 73.19M | 92.65M | 47.00M | 67.46M |
| Cash, Cash Equivalents and Short-Term Investments | 32.53M | 12.87M | 16.63M | 41.78M | 26.19M | 47.91M |
| Total Debt | 30.60M | 22.93M | 23.51M | 62.94M | 1.70M | 2.04M |
| Total Liabilities | 41.13M | 38.99M | 51.39M | 74.21M | 5.78M | 5.53M |
| Stockholders Equity | 48.16M | 9.28M | 21.80M | 18.44M | 41.22M | 61.93M |
Cash Flow | ||||||
| Free Cash Flow | -20.57M | -23.94M | -16.13M | -17.03M | -21.82M | -12.31M |
| Operating Cash Flow | -19.14M | -23.60M | -14.87M | -16.43M | -20.51M | -10.64M |
| Investing Cash Flow | -2.44M | -1.43M | -9.00M | -25.04M | 18.70M | -21.90M |
| Financing Cash Flow | 28.36M | 26.09M | -1.30M | 56.90M | 232.00K | 51.65M |
Avacta Group plc Technical Analysis
Avacta Group plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £113.64M | 14.97 | 64.40% | 7.06% | -3.61% | -6.38% | |
64 Neutral | £44.66M | 4.14 | ― | 3.05% | 11.92% | -33.76% | |
53 Neutral | £311.64M | ― | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £5.16M | -4.90 | -5.41% | ― | -20.31% | -19.35% | |
46 Neutral | £102.22M | -7.46 | ― | ― | ― | -94.12% | |
39 Underperform | £121.56M | -7.90 | -209.34% | ― | 198.49% | -26.66% |
Avacta Group plc Corporate Events
Avacta Group PLC has unveiled its first preclinical data for its dual payload pre|CISION® technology at the 2025 AACR-NCI-EORTC International Conference. This innovative approach delivers two therapeutic payloads simultaneously to the tumor microenvironment, potentially overcoming resistance mechanisms and enhancing tumor control. The company’s dual payload pipeline includes combinations of microtubule inhibition and topoisomerase I inhibition, as well as DNA damage response agents combined with exatecan. The pre|CISION® platform has shown promising results in terms of tumor selectivity and therapeutic efficacy, offering a novel approach to cancer therapy with significant implications for treating highly-resistant tumors.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £63.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group PLC announced an upcoming presentation of their pre|CISION® dual payload peptide drug conjugate delivery system data, following their participation in the 2025 AACR-NCI-EORTC International Molecular Targets Congress. The presentation, scheduled for October 29, 2025, will be accessible to existing and potential shareholders, allowing them to engage with the company’s leadership and submit questions, potentially impacting Avacta’s market engagement and stakeholder relations.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £63.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group plc has successfully raised approximately £16 million through an oversubscribed equity placement, which will provide additional working capital to advance its research and development programs into the second half of 2026. The funds will support the progression of the faridoxorubicin Phase 1b trial and the initiation of the FAP-EXd Phase Ia trial, while also allowing Avacta to maintain full ownership of its promising programs based on its pre|CISION® technology. This financial move also facilitates the deferment of certain convertible bond repayments, extending the company’s cash runway and enabling it to continue building its intellectual property estate.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £75.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group PLC announced promising results from its Phase 1a clinical trial of faridoxorubicin, presented at the European Society of Medical Oncology Annual Congress. The trial demonstrated favorable safety and tolerability, with no severe cardiac toxicity observed even at higher doses, and a significant improvement in progression-free survival for patients with salivary gland cancers. These findings highlight the potential of Avacta’s pre|CISION® platform to offer new treatment options for cancer patients, particularly those with limited therapeutic choices, and underscore the platform’s ability to protect normal tissues from toxicity while maintaining efficacy.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £75.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group PLC announced the presentation of data on its first dual-payload peptide drug conjugate (PDC) at an upcoming international conference. This development marks a significant advancement in oncology therapy, as it allows for the selective and controlled release of two cancer-targeting drugs from a single molecule, potentially enhancing treatment effectiveness and addressing resistance mechanisms in tumors.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £75.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group plc’s recent earnings call reflects a company making notable strides in its clinical programs and preclinical data, bolstered by strategic collaborations that enhance market potential. However, financial constraints and the lack of secured partnerships present challenges, with shareholder concerns about the share price remaining unaddressed.
Avacta Group plc has reported its interim results for the first half of 2025, highlighting significant progress in its clinical programs, particularly the faridoxorubicin (AVA6000) Phase 1b trial, which has shown promising initial clinical activity. The company has also renegotiated the terms of its Heights Convertible Bond and raised £6.5 million to fund upcoming bond payments, reflecting growing confidence in its R&D pipeline. Avacta anticipates multiple pipeline updates in late 2025, including data from its faridoxorubicin program, which could enhance its industry positioning and stakeholder interest.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £47.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group plc has announced that it will release its unaudited interim results for the first half of 2025 on September 30, with a live presentation by its CEO and CFO accessible to shareholders and potential investors. Additionally, the company has updated the schedule for its presentation at the European Society for Medical Oncology Congress, where it will discuss its Phase I trial of FAP-Dox (AVA6000) in patients with FAP-positive solid tumors. These announcements highlight Avacta’s ongoing efforts to engage with stakeholders and advance its position in the oncology drug development sector.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £47.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group plc has announced that its pre|CISION® platform has been shortlisted for the Technology of the Year Award at the AIM Awards, an event recognizing the achievements of fast-growing publicly quoted companies. This nomination highlights Avacta’s innovative approach to cancer treatment, which could enhance its market position and stakeholder confidence by showcasing its potential to revolutionize oncology drug delivery.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £47.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group plc has completed the sale of its entire issued share capital of Coris Bioconcept SRL to 3B BlackBio Dx Ltd, following the satisfaction of all closing conditions. This strategic move is expected to impact Avacta’s operations by allowing the company to focus more on its core business of developing targeted oncology drugs, potentially strengthening its position in the life sciences industry.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £47.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group plc has announced amendments to its Convertible Bond and a successful equity fundraise of £3.25 million. The funds will be used to settle an upcoming bond repayment, while the bond amendments include deferred repayments and a new conversion price. This strategic move reflects Avacta’s progress in its oncology platform and strengthens its financial position, potentially enhancing its market position and stakeholder confidence.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £47.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group PLC announced its presentation of updated data from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 European Society for Medical Oncology Congress. The data, focusing on patients with FAP-positive solid tumors, highlights Avacta’s ongoing efforts in the clinical development of its innovative oncology drug, which aims to improve targeted cancer therapy. This presentation underscores Avacta’s commitment to advancing its pipeline and strengthening its position in the oncology drug market.